CD19 CAR T cells for multiple sclerosis: Forging further into the new frontier

Alexander W Rankin; Nirali N Shah

doi:10.1016/j.medj.2024.04.005

CD19 CAR T cells for multiple sclerosis: Forging further into the new frontier

Med. 2024 Jun 14;5(6):482-484. doi: 10.1016/j.medj.2024.04.005.

Authors

Alexander W Rankin¹, Nirali N Shah²

Affiliations

¹ Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
² Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: [email protected].

PMID: 38878763
DOI: 10.1016/j.medj.2024.04.005

Abstract

The efficacy of CD19 chimeric antigen receptor (CAR) T cells in B cell malignancies has generated recent interest in their application to other B cell-related pathologies, such as autoimmune diseases. Fischbach et al.¹ report on the use of CD19 CAR T cells in two patients with progressive multiple sclerosis, demonstrating feasibility and safety for the first time in this disease process.

Published by Elsevier Inc.

MeSH terms

Antigens, CD19* / immunology
Humans
Immunotherapy, Adoptive* / methods
Multiple Sclerosis* / immunology
Multiple Sclerosis* / therapy
Receptors, Antigen, T-Cell / immunology
Receptors, Chimeric Antigen* / immunology
T-Lymphocytes / immunology

Substances

Antigens, CD19
Receptors, Chimeric Antigen
Receptors, Antigen, T-Cell